---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-037151"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2023-02-14T23:59:59+00:00"
generated_at: "2026-06-19T14:21:40.857079+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine raises $62.5M in registered direct offering led by Bain Capital Life Sciences

## Summary
- Gross proceeds $62.5M from offering of 1,488,166 shares at $23.00 and pre-funded warrants for 1,229,224 shares.
- Bain Capital Life Sciences contributed $50M; existing investors Access Biotechnology and OrbiMed also participated.
- Net proceeds to fund clinical development of bitopertin, DISC-0974, MWTX-003 and for working capital.
- Offering expected to close on or about February 15, 2023.

## SEC filing metadata
- accession: 0001193125-23-037151
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2023-02-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312523037151/0001193125-23-037151-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312523037151/d289637d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-037151
- JSON: https://secwatch.observer/filing/0001193125-23-037151.json
- Plain text: https://secwatch.observer/filing/0001193125-23-037151.txt

## Key facts
- Material Agreements
  Disc Medicine, Inc. entered into Purchase Agreement with the investors identified therein valued at approximately $62.5 million (effective 2023-02-13).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the investors identified therein
  - Value: approximately $62.5 million
  - Effective: 2023-02-13
  source text: On February 13, 2023, Disc Medicine, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the investors identified therein.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816736/000119312523037151/0001193125-23-037151-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.